prIME Podcasts provide evidence-based, state-of-the-art educational discussions that assist oncology clinicians in making up-to-date and appropriate treatment decisions.
If you’d like to receive automatic downloads (free of charge) to your iTunes account when new prIME Podcasts become available, please subscribe to our Podcast.
*To subscribe to the prIME Podcast iTunes channel, please click on the Podcast link above. Then, click on the blue View in iTunes button in the left column. Once on the prIME Podcast channel page (with iTunes installed on your computer), click on the Subscribe Free button in the left column. When new prIME Podcasts become available, they will be automatically downloaded to your iTunes account, free of charge.
If you would rather not subscribe, each individual podcast is available for free download. Please visit our iTunes channel and click on the Free button on the right side of the individual podcast listing.
*To subscribe to our RSS feeds, you'll need an RSS reader — a program that displays feeds from sites that you select. There are many readers available. Once you have chosen a news reader simply click on the links above or copy the feed address and paste it into an RSS news reader, or use a browser which supports RSS feeds, such as Chrome, Safari, Firefox, or Internet Explorer.
These short interviews with key thought leaders in the field focus on the definition of myeloproliferative neoplasms (MPNs); curative and palliative therapies for MPNs; current therapies for the treatment of MPNs; the discovery of the JAK-STAT pathway and the subsequent identification of the activating mutation, JAKV617F,which lead to the development of targeted therapies for MPNs; and the results of the pivotal phase II trials in myelofibrosis.
Francisco Cervantes, MD, PhD, from Hospital Clinic, Barcelona, Spain, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss how to define MPNs, recent changes in the classification system, and risk assessment with the IPSS and dynamic IPSS (DIPSS).
Claire Harrison, DM, from St Guy's and St Thomas' Trust, London, United Kingdom, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss the only potentially curative therapy for MPNs, allogeneic stem cell transplant (allo-SCT), as well as palliative therapies.
Jean-Jacques Kiladjian, MD, PhD, from Hôpital Saint-Louis, Paris, France, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss the discovery of the JAK-STAT pathway and the subsequent identification of the activating mutation, JAKV617F.
Srdan Verstovsek, MD, PhD, from University of Texas, M. D. Anderson Cancer Center, Houston, Texas, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, review the abstracts that examined the overall survival in patients with MF treated with ruxolitinb in clinical trials.
Ruben Mesa, MD, from Mayo Clinic, Scottsdale, Arizona, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, summarize the pivotal phase II trials in myelofibrosis, COMFORT-I and COMFORT-II, with specific attention to the Quality of Life assessment in these trials.
Alessandro Vannucchi, MD, PhD, from University of Florence, Florence, Italy, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss therapies currently being studied in clinical trials for treatment of MPNs.
Hagop Kantarjian, MD, from the University of Texas, M. D. Anderson Cancer Center, Houston, Texas, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss issues in the initial management of chronic-phase chronic myelogenous leukemia
Junia Melo, MD, PhD, from the Center for Cancer Biology, Adelaide, South Australia, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss maintenance therapy for patients with CP-CML.
John Gribben, MD, from Barts and the London School of Medicine, London, United Kingdom, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss the role of molecular profiling in the diagnosis and management of chronic lymphocytic leukemia.
Jan Burger, MD, PhD, from the University of Texas, M. D. Anderson Cancer Center, Houston, Texas, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss therapy options for patients with chronic lymphocytic leukemia.
Dieter Hoelzer, MD, PhD, from University of Frankfurt, Germany, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss recent progress in the management of adult acute lymphoblastic leukemia.
Daniel Link, MD, PhD from Washington University, St Louis, Missouri, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss genomic sequencing in acute myeloid leukemia.
Timothy Illidge, MD, from Christie Hospital in Manchester, United Kingdom, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss the role of radioimmunotherapy in non-Hodgkin lymphoma.
Franco Cavalli, MD, from the Oncology Institute of Southern Switzerland in Bellinzona, Switzerland and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss personalized therapy for patients with non-Hodgkin lymphoma.
Michael Pfreundschuh, MD, from the Saarland University Medical School in Homburg, Germany, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss personalized therapy for patients diffuse large B-cell lymphoma.
Emilio Montserrat, MD, from the Hematology and Oncology Hospital Clinic, University of Barcelona, Spain, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss personalized therapy for patients with chronic lymphocytic leukemia.
Christian Gisselbrecht, MD, from Hospital Saint Louis in Paris, France, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss personalized therapy for patients with mantle cell lymphoma.
James O. Armitage, MD, from the University of Nebraska Medical Center in Omaha, Nebraska, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss personalized therapy for patients with follicular lymphoma.
